Valeant Pharma to Restate Earnings After Board Review

The transcript discusses Valiant's financial investigation, revealing issues with revenue recording and a $58 million adjustment. It highlights the scrutiny from the healthcare system and market reactions, including Deutsche's downgrade of Express Scripts. Analysts have mixed opinions, with some optimistic and others, like David Maris, skeptical. The stock has seen significant fluctuations, and the future outlook remains uncertain amid ongoing challenges.

What are the implications of the scrutiny from the healthcare system on Valiant's operations?

What was David Maris's stance on Valiant's strategy and what price target did he suggest?